Sign in

Private company

Hutchison MediPharma Limited

Hutchison MediPharma Limited is a biopharmaceutical company.1 It is headquartered in Hong Kong.1

Last updated Oct 21, 2026.

Overview

  • Industrypharmaceutical industry1
  • HeadquartersHong Kong1
  • Websitewww.hutch-med.com
  • Listed onNasdaq (HCM), Hong Kong Stock Exchange (0013)1

See how the biggest companies compare on our leaderboards

Timeline

  1. Jun 23, 2021Went public Listed on Hong Kong Stock Exchange1
  2. 2016Went public Listed on NASDAQ1

Calendar

Drug trials and FDA: recently

  1. Apr 21, 2026Phase 2 trial completed Phase 2 trial of Savolitinib in Gastric Cancer: primary completion Apr 21, 2026, no results posted yet (ClinicalTrials.gov NCT04923932).2
  2. Aug 23, 2024Phase 2 trial completed Phase 2 trial of osimertinib and savolitinib in Carcinoma, run by AstraZeneca: primary completion Aug 23, 2024, results posted Feb 10, 2026 (ClinicalTrials.gov NCT03778229).3

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). Trials from ClinicalTrials.gov, as the sponsor registered them (expected dates are the sponsor's own and often move); approvals and advisory committee meetings from the FDA. The FDA does not publish its decision (PDUFA) dates. The full markets calendar

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3